A research blend of retatrutide and cagrilintide studied for complementary metabolic signalling pathways.
This research blend pairs retatrutide, a triple agonist studied at the GLP-1, GIP, and glucagon receptors, with cagrilintide, a long-acting amylin analog. Both are researched in the context of metabolic and appetite-regulation signalling in laboratory and animal models. The combination is examined for how distinct receptor systems may act in parallel on energy-balance pathways.
Researchers study the blend to explore complementary incretin and amylin signalling within a single preparation. Both components are active subjects in metabolic research.
Retatrutide is studied at GLP-1, GIP, and glucagon receptors in models.
Cagrilintide is researched as an amylin analog influencing satiety signalling.
The blend is examined for parallel effects on energy-balance pathways.
Studied for how incretin and amylin systems may act complementarily.
Bring the vial (10 mg + 2.5 mg) and bacteriostatic water to room temperature.
Add bacteriostatic water slowly along the glass wall — the volume you add sets the concentration.
Swirl gently (do not shake) until fully clear, then refrigerate at 2–8 °C.
The two components combine triple-agonist and amylin signalling research interest.
Explored alongside other incretin-research agents in metabolic work.
Links open a PubMed search for the topic. They point to independent literature and are provided for orientation in a research context only.
They are studied together for complementary incretin and amylin metabolic signalling.
Retatrutide is a triple receptor agonist; cagrilintide is a long-acting amylin analog.
No. This is a research blend intended for laboratory research only.
See the product, or build a stack around it.
View product →Open Stack-Builder →
You must be at least 21 years old to enter this website.
By clicking "Confirm & Enter", you confirm that you are 21 years of age or older and understand that all products sold on this website are intended for research purposes only.
